Short description
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development
Description
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs
Last funding
Cannot Access
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Cupertino, California, United States, North America
Founded on
January 1, 1998
Exited on
October 6, 2000
Went public on
October 6, 2000
Stock symbol
DRRX
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noway Youcantaccess
Sign in for full access
Founders
James E. Brown